Key Highlights
- Novo Nordisk initiated legal proceedings against Eli Lilly in New Jersey’s U.S. District Court this Tuesday
- The legal action alleges that Lilly’s marketing campaigns for Zepbound and Mounjaro rely on obsolete clinical studies to showcase superiority
- Lilly’s promotional materials pit their maximum dosages against earlier, lower-strength versions of Wegovy and Ozempic, omitting recent high-dose findings
- According to Novo, the high-strength Wegovy formulation (7.2mg) delivers approximately 47 pounds of average weight reduction, matching Zepbound’s roughly 48 pounds
- Novo demands judicial intervention to remove the advertisements, mandates corrective marketing efforts, and requests monetary compensation
Shares of Novo Nordisk (NVO) declined approximately 1.4% while Eli Lilly (LLY) experienced a roughly 2.7% drop this Tuesday following Novo’s legal filing that accuses Lilly of disseminating deceptive promotional content about its weight-management medications.
The legal complaint was submitted to the U.S. District Court for the District of New Jersey. Novo contends that Lilly breached the Lanham Act, in addition to violating federal and state regulations concerning deceptive advertising and anti-competitive business practices.
The dispute revolves around extensive television and digital media advertisements promoting Lilly’s weight-loss medication Zepbound and its diabetes therapy Mounjaro.
According to Novo, these marketing materials rely on antiquated clinical trial results to present Lilly’s products in a more favorable light. One television advertisement, which has generated more than 700 million viewer impressions since late April, informs audiences that Zepbound users experience an average weight reduction of 50 pounds compared to 33 pounds with Wegovy.
The issue, as Novo explains, is that the 33-pound statistic derives from studies utilizing earlier, lower-strength versions of Wegovy ā completely excluding the recently approved 7.2-milligram dosage that received authorization in March 2025.
According to Novo’s data, the high-strength Wegovy formulation demonstrated average weight loss of approximately 47 pounds in contemporary clinical trials. This figure closely parallels Zepbound’s 48-pound average from Lilly’s most current research.
“It creates an unavoidable impression among consumers that Lilly’s products deliver superior results compared to Novo’s, which is fundamentally incorrect,” stated John Kuckelman, who serves as Novo’s group general counsel.
Lilly’s Response to Prior Cease-and-Desist Demand
Novo maintains this dispute has a history. The pharmaceutical company delivered an official cease-and-desist notification to Lilly in April, immediately following the regulatory approval of the high-dose Wegovy formulation.
Lilly chose not to withdraw the promotional materials. Rather, Novo alleges, the company incorporated what it characterizes as an “unclear, perplexing, and barely readable” footnote recognizing the higher-dose option’s existence ā while failing to transparently communicate its enhanced efficacy.
Novo now requests the court to issue a permanent injunction against the advertisements, mandate that Lilly execute corrective advertising campaigns, and provide monetary restitution. Should Lilly refuse to voluntarily discontinue the promotional content, Novo indicates it will pursue a preliminary injunction to immediately halt the ads during litigation.
Lilly has not issued any statement in response to media inquiries.
Ozempic and Mounjaro Comparison Under Scrutiny
The litigation extends beyond the Zepbound and Wegovy comparison. Novo further contends that Lilly employed identical misleading strategies when contrasting Mounjaro with Ozempic ā deliberately omitting information about a higher-strength Ozempic formulation that received approval more than four years ago.
Direct comparative clinical studies between the maximum approved strengths of Wegovy and Zepbound have not been conducted. Novo argues this absence of head-to-head data means Lilly lacks “any legitimate foundation” for asserting superior effectiveness over Novo’s current product portfolio.
“Though such statements might have held validity prior to the 7.2-milligram Wegovy formulation becoming available, they no longer represent an accurate characterization,” Kuckelman explained.
The Zepbound television commercial by itself has accumulated over 700 million impressions since its debut at approximately the conclusion of April.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
